WO2013105801A1 - Sonde pour le typage du génotype de fusion de leucémie myéloïde chronique, amorce et leur procédé d'utilisation - Google Patents

Sonde pour le typage du génotype de fusion de leucémie myéloïde chronique, amorce et leur procédé d'utilisation Download PDF

Info

Publication number
WO2013105801A1
WO2013105801A1 PCT/KR2013/000219 KR2013000219W WO2013105801A1 WO 2013105801 A1 WO2013105801 A1 WO 2013105801A1 KR 2013000219 W KR2013000219 W KR 2013000219W WO 2013105801 A1 WO2013105801 A1 WO 2013105801A1
Authority
WO
WIPO (PCT)
Prior art keywords
primer
capture probe
seq
myeloid leukemia
present
Prior art date
Application number
PCT/KR2013/000219
Other languages
English (en)
Korean (ko)
Inventor
채치범
김동욱
강종훈
최수영
Original Assignee
건국대학교 산학협력단
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 건국대학교 산학협력단, 가톨릭대학교 산학협력단 filed Critical 건국대학교 산학협력단
Publication of WO2013105801A1 publication Critical patent/WO2013105801A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Definitions

  • the present invention relates to a capture probe and primer set for chronic myeloid leukemia fusion genotype typing and a method for detecting chronic myeloid leukemia fusion genotype using the same, more specifically, reverse transcription reaction, polymerase chain reaction, genetic modification and hybridization on the surface of a solid support
  • Type of BCR-ABL modified protein with significantly improved sensitivity and accuracy by promoting the formation of a branched nucleic acid complex between a capture probe capable of detecting the type of BCR-ABL modified protein and amplified target DNA by performing integration of It relates to a detection method.
  • Leukemia is a general term for diseases in which leukocytes proliferate abnormally. Types of leukemia are divided into “myeloid leukemia” and “lymphoid leukemia” according to the leukocyte origin of leukemia, and divided into acute leukemia and chronic leukemia. The clinical manifestations of leukemia vary depending on the type of disease and the nature of the cells involved.
  • CML chronic myelogenous leukemia
  • the most common cause is known to be caused by translocation of the chromosome, in particular, the chromosome 9 and chromosome 22
  • Translocation is known to be the main cause of illness. Indeed, in 95% of patients with chronic myeloid leukemia, translocations between chromosome 9 and chromosome 22 are found. It is formed by translocation to the breakpoint cluster region (BCR) gene present at the 2nd position, and this rearrangement is called BCR-ABL rearrangement. Chromosomes with rearranged BCR-ABL genes are called Philadelphia chromosomes.
  • BCR breakpoint cluster region
  • Myeloid leukemia has an incidence of 1-2 out of 100,000 people every year, more male than female, and more than 50 adults. Especially in western countries, 15-20% of adult leukemia patients are myeloid leukemia patients.
  • ALL acute lymphoblastic leukemias
  • ALL Philadelphia chromosomes with BCR-ABL genes are detected in 20-25% of ALL patients.
  • Chronic myeloid leukemia caused by the previous BCR-ABL rearrangement is very effective in treating imatinib mesylate sold under the trademark GlivecTM as a special drug. This is very important for determining the treatment direction and prognostic judgment.
  • leukemia diagnostic methods include blood tests, peripheral blood smears, bone marrow tests, immunophenotyping tests, cytogenetic tests for chromosome structure and abnormalities, but tumors with the same findings differ greatly from patient to patient. Since clinical results and response to various treatments may be different, diagnosis and classification according to pathology and morphological specificity have limited limitations in determining a suitable treatment method for treating leukemia. In recent years, molecular genetics have been developed and leukemia-specific chromosomes and genes have been identified in more than 80-90% of malignant blood diseases. Situ hybridization and polymerase chain reaction (PCR) have been used to improve diagnostic success rates. Nevertheless, the diagnostic accuracy for determining the type of leukemia is only about 30 to 40%, and the disadvantage that the time required for diagnosis is long is not improved.
  • PCR polymerase chain reaction
  • M-bcr type More than 95% of patients with CML are M-bcr type, that is, b3a2 type (or e14a2) with BCR gene exon 14 and ABL gene exon 2, and b2a2 type (or b13a2 type) with BCR exon 13 and ABL exon2.
  • M-bcr type detected in a small number of CML patients includes the e1a2 gene, which is a combination of BCR exon 1 and ABL exon 2, which occurs in 60-70% of ALL patients.
  • Another c3a2 gene in a small number of CML patients is a combination of BCR exon 19 and ABL exon 2.
  • These four fusion genes, b3a2, b2a2, e1a2, and c3a2 have more than 98% of CML patients.
  • the present invention has been made to solve the above problems in the prior art, and an object thereof is to provide a capture probe and primer set for detecting chronic myeloid leukemia type. It is also an object of the present invention to provide a composition and kit for detecting chronic myeloid leukemia type comprising the capture probe and primer set. Another object of the present invention is to provide a chronic myeloid leukemia type detection method using the capture probe and primer set.
  • the present invention provides a capture probe for chronic myeloid leukemia fusion genotype typing, comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6-12.
  • the present invention provides a primer for chronic myeloid leukemia fusion genotype typing, comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 5.
  • the primer set includes a nucleotide sequence of SEQ ID NO: 5 which is a reverse primer, and at least one selected from the group consisting of SEQ ID NOs: 1 to 4, which is a forward primer It is characterized by including the nucleotide sequence.
  • the primer set is characterized by mixing the forward primer and the reverse primer in a ratio of 1: 1 to 1:10.
  • the primer set is characterized in that labeled with a fluorescent molecule or biotin (biotin) at the 5 'end.
  • the present invention provides a kit for chronic myeloid leukemia fusion genotyping, comprising the composition for detecting the chronic myeloid leukemia type.
  • the present invention is to obtain a cell extract by crushing the cells extracted from bone marrow or peripheral blood;
  • the cell extract is mixed with a chronic myeloid leukemia fusion genotype typing primer set, DNA polymerase, reverse transcriptase, dNTP (dATP, dCTP, dTTP, dGTP), and a buffer to prepare a reaction mixture.
  • a chronic myeloid leukemia fusion genotype typing primer set DNA polymerase, reverse transcriptase, dNTP (dATP, dCTP, dTTP, dGTP), and a buffer to prepare a reaction mixture.
  • dNTP dATP, dCTP, dTTP, dGTP
  • step Delivering the reaction mixture to a solid support surface to which a capture probe for chronic myeloid leukemia fusion genotyping typing is immobilized; Reverse transcription of RNA in the reaction mixture into cDNA; Amplifying the breakpoint cluster region-abelson oncogene (BCR-ABL) gene in the cDNA by an asymmetric polymerase chain reaction; Heating and denaturing the amplified gene; performing hybridization between the denatured gene and the capture probe in a reaction mixture comprising dNTPs, primers, and polymerases to promote the formation of branched nucleic acid complexes; And it provides a method for detecting chronic myeloid leukemia fusion genotype, comprising the step of detecting the branched nucleic acid complex.
  • BCR-ABL breakpoint cluster region-abelson oncogene
  • the capture probe is characterized in that it is fixed to the surface of the solid support by adding an amine group at the 5 'end using a carbon linker (carbon linker).
  • the step of obtaining the cell extract is characterized in that the supernatant is obtained by centrifugation after crushing the cells by heating for 3 to 10 minutes at 90 °C to 100 °C.
  • the reverse transcription step and the asymmetric polymerase chain reaction step are characterized in that it is carried out integrated.
  • the step of denaturing the gene is characterized in that for 3 to 10 minutes heating at 90 °C to 100 °C.
  • the hybridization step is characterized in that the reaction at 50 °C to 60 °C for at least one hour.
  • the method for detecting chronic myeloid leukemia fusion genotype is characterized in that all processes are performed in a single reaction mixture.
  • the detecting of the branched nucleic acid complex is characterized by measuring fluorescence labeled on the primer.
  • the detecting of the branched nucleic acid complex is characterized by measuring using streptavidin (streptavidin) to which a biotin labeled with a primer and a fluorescence or colorable enzyme are linked.
  • streptavidin streptavidin
  • the method of detecting chronic myeloid leukemia fusion genotype is characterized in that it further comprises the step of extracting RNA from the cell.
  • Chronic myeloid leukemia fusion genotype detection method using the capture probe and primer of the present invention integrates reverse transcription, asymmetric polymerase chain reaction, and hybridization, which significantly improves sensitivity and reduces detection time compared to the conventional method. In addition, automation of the detection phase is possible. In addition, there is a significant increase in the signal and sensitivity through the integration process, the specificity of the capture probe and primer of the present invention is very high, it is possible to accurately detect the chronic myeloid leukemia type early. Therefore, it is expected that it can be importantly applied to more effectively treat chronic myeloid leukemia and determine its prognosis.
  • 1 is a schematic diagram showing the location of the primer and capture probe of the present invention binds to chimeric BCR-ABL mRNA.
  • FIG. 2 is a diagram showing the results of confirming specificity of primers and capture probes using a plasmid containing chimerical BCR-ABL cDNA.
  • 3 is a diagram showing the result of confirming whether a mixed expression of two or more fusion genes can be detected using the primer and capture probe of the present invention with a mixture of plasmids containing the cDNA of BCR-ABL.
  • FIG. 4 is a diagram showing the result of amplifying the signal and detection sensitivity through the integrated reverse transcription, asymmetric PCR and hybridization reaction performed in the solid phase in which the capture probe of the present invention is immobilized.
  • FIG. 5 is a view showing the results of measuring the detection limit of the expression level of the BCR-ABL fusion gene of the DNA microarray using integrated reverse transcription, asymmetric PCR and hybridization reaction performed on the solid phase in which the capture probe of the present invention is immobilized. .
  • Figure 6 shows the results of detecting the BCR-ABL fusion gene type from the RNA of chronic myelogenous leukemia patients using DNA microarray using integrated reverse transcription, asymmetric PCR and hybridization reaction performed on a solid phase in which the capture probe of the present invention is immobilized. The figure which shows.
  • the present inventors have completed the present invention as a result of studying a detection method capable of confirming a type of a breakpoint cluster region-abelson oncogene (BCR-ABL) modified protein which is simple but has improved sensitivity and accuracy.
  • BCR-ABL breakpoint cluster region-abelson oncogene
  • the present invention includes a capture probe for chronic myeloid leukemia fusion genotype typing and a base sequence selected from the group consisting of SEQ ID NOs: 1 to 5, including a base sequence selected from the group consisting of SEQ ID NOs: 6 to 12. It provides a primer for chronic myeloid leukemia fusion genotype typing.
  • the present inventors prepared primers and capture probes based on the sequence of BCR mRNA (accession number X02596) and ABL mRNA (accession number X16416) to prepare primers and capture probes having specificity according to the BCR-ABL type.
  • Reverse primers A2-R (SEQ ID NO: 5) of the primers of the present invention were designed to bind to the ABL A2 exon and A3 exon boundary sites so that PCR only occurs from cDNA produced by reverse transcription from RNA.
  • Capture probes B3-P, B2-P, E1-P, C3-P, and A2-P of the present invention (SEQ ID NOs: 6, 7, 8, and 9) simultaneously and reproducibly express the expression of BCR-ABL fusion and normal genes. For detection, it was designed to specifically bind to each BCR cluster region (exon 1, exon 13, exon 14) and ABL exon 2 moiety.
  • Capture probes B3A2, and B2A2 (SEQ ID NOS: 10 and 11) of the present invention are BCR-ABL of each type (B2A2, B3A2) to further distinguish between B3A2 type fusion gene expression and B3A2 and B2A2 type fusion gene mixed expression. It is designed to bind to the genetic boundary part.
  • the locations where the primers and capture probes of the invention bind onto chimeric BCR-ABL mRNAs are shown in FIG. 1.
  • B2, B3, and C3 in FIG. 1 represent BCR exon portions that include breakpoints.
  • the base sequences of SEQ ID NOs: 1 to 4 are forward primers, and the base sequences of SEQ ID NO: 5 are reverse primers, and are reverse for use in polymerase chain reaction (PCR).
  • the primer specifically amplifies the BCR-ABL type of the target, it was confirmed that the probe is bound to each BCR-ABL type, and also different BCR using a DNA microarray It was confirmed that the type of chronic myeloid leukemia can be detected in the sample mixed with the -ABL fusion gene (see Example 1).
  • the present invention includes the capture probe and primer set for chronic myelogenous leukemia fusion genotype typing, and DNA polymerase, reverse transcriptase, dNTP (dATP, dCTP, dTTP, dGTP), and a buffer solution.
  • dNTP reverse transcriptase
  • dNTP reverse transcriptase
  • the present invention also provides a kit for chronic myeloid leukemia fusion genotyping, comprising the composition for chronic myeloid leukemia fusion genotyping.
  • the detection signal is increased in the case of asymmetric PCR (proportion of the forward primer and reverse primer 1:10) compared to symmetric PCR (proportion of the forward primer and reverse primer 1: 1)
  • asymmetric PCR proportion of the forward primer and reverse primer 1:10
  • symmetric PCR proportion of the forward primer and reverse primer 1: 1
  • the detection signal was increased by 15 times or more compared with hybridization only on the glass slide. .
  • the present invention is a step of crushing cells extracted from bone marrow or peripheral blood by heating at 90 °C to 100 °C for 3 minutes to 10 minutes, and then centrifuged to obtain a supernatant (cell extract);
  • the cell extract is mixed with a chronic myeloid leukemia fusion genotype typing primer set, DNA polymerase, reverse transcriptase, dNTP (dATP, dCTP, dTTP, dGTP), and a buffer to prepare a reaction mixture.
  • step Delivering the reaction mixture to a solid support surface to which a capture probe for chronic myeloid leukemia fusion genotyping typing is immobilized; Reverse transcription of the RNA in the reaction mixture into cDNA and simultaneously amplifying a breakpoint cluster region-abelson oncogene (BCR-ABL) gene in an asymmetric polymerase chain reaction in the reverse transcribed cDNA; Denaturation of the amplified gene by heating at 90 ° C. to 100 ° C.
  • BCR-ABL breakpoint cluster region-abelson oncogene
  • any method of detecting chronic myeloid leukemia type using the primer and capture probe of the present invention is not limited thereto.
  • the detection method may further include extracting RNA from the cell extract to improve accuracy.
  • nucleic acid complex there is no limitation on how the nucleic acid complex can be detected.
  • methods of labeling primers methods of incorporating fluorescently labeled dNTPs, staining using DNA staining reagents (e.g., EtBr, SYBR green, etc.), binding to capture probes using biotin-labeled primers DNA is combined with streptavidin (fluorescent material or enzyme-linked streptavidin), and then a method of measuring a signal through an enzymatic reaction.
  • the genetic modification means forming a single strand of DNA, and typically, at a temperature above 90 ° C., the double strand of DNA is separated into a single strand of DNA.
  • Hybridization refers to the formation of a duplex between two strands of single stranded DNA or the formation of a double helix between the DNA and RAN chains by base complementarity.
  • the branched nucleic acid complex refers to an aggregated form of DNA having side chains in which at least three single-stranded DNAs partially bind to each other.
  • the solid support means a substrate to which a capture probe for detecting a target nucleic acid can be attached. There is no restriction on the kind of the solid support.
  • the substrate may be a flat substrate such as a glass slide, metal, or plastic, which may combine an array of capture probes, but a spherical substrate such as glass, plastic, or polymer beads may be used. That is, a substrate of various materials such as a tube may be used.
  • a linker molecule may be fixed to the 3 'or 5' end of the probe, but is not limited thereto.
  • B2-F, E1-F (SEQ ID NOs: 1 and 2) of the present invention are designed to bind to each BCR exon 13, exon 1 sequence, and C3-F (SEQ ID NO: 3) binds to a BCR exon 18 sequence It was designed to The forward primer A2-F (SEQ ID NO: 4) of the present invention was designed to bind to the ABL exon2 sequence.
  • the reverse primers A2-R (SEQ ID NO: 5) of the present invention were designed to bind to the ABL A2 exon and A3 exon border sites so that PCR only occurs from cDNA produced by reverse transcription from RNA.
  • Capture probes B3-P, B2-P, E1-P, C3-P, and A2-P of the present invention (SEQ ID NOs: 6, 7, 8, and 9) simultaneously and reproducibly express the expression of BCR-ABL fusion and normal genes. For detection, it was designed to specifically bind to each BCR cluster region (exon 1, exon 13, exon 14) and ABL exon 2 region.
  • Capture probes B3A2, B2A2 (SEQ ID NOs: 10 and 11) of the present invention are BCR-ABL genes of each type (B2A2, B3A2) to further distinguish between B3A2 type fusion gene expression and B3A2 and B2A2 type fusion gene mixed expression. It is designed to join to the boundary. The sequence and position are shown in Table 1 and FIG. Primers other than the A2-F primers were labeled with fluorescent molecules (Cy3) at the 5 'end, and the capture probes were immobilized on the solid phase using an amine group at the 5' end.
  • the plasmid was prepared by PCR reaction mixture (dNTP (200 uM, dATP, dGTP, dCTP, dTTP), buffer on a glass slide with a capture probe fixed). Mixed with solution (10 mM Tris-HCl (pH 8.3), 50 mM KCl), DNA polymerase (2U Taq DNA polymerase), primer set) followed by PCR (5 minutes at 95 ° C, 15 seconds at 94 ° C, 15 seconds at 55 ° C. and 15 seconds at 72 ° C. were repeated for 45 times), and then denatured by heating at 94 ° C.
  • b3a2 (lane 1) is 394 bp and 183 bp
  • b2a2 (lane 2) is 319 bp and 183 bp
  • e1a2 (lane 3) is 353 bp and 183 bp
  • c3a2 (lane 4) is 361 bp and 183 bp
  • a2 (lane 5) was confirmed that the 183 bp gene was amplified.
  • the A2-P capture probes could be confirmed by fluorescence, regardless of the BCR-ABL type, and the B3-P, B2-P, E1-P, and C3-P capture probes. It was confirmed that specifically bound to each according to the BCR-ABL type. The specificity of the prepared primer and capture probe was confirmed through the results.
  • the product amplified by PCR was confirmed that the correct size, even if a variety of genes are mixed BCR to B3-P, B2-P, E1-P, and C3-P capture probes, respectively It was confirmed that the specific binding according to the -ABL type.
  • the specific binding according to the -ABL type Even when different types of chimeric BCR-ABL RNA were mixed, it was confirmed that the type of chronic myeloid leukemia could be accurately detected using the prepared primers and capture probes.
  • RNA extracted from K562 cells containing b3a2 RNA (10,000 molecules) as a sample was analyzed by one-step RT-PCR reaction mixture, namely reverse transcriptase, Taq DNA polymerase, dNTP, PCR primer, and buffer solution. It was added to the solution containing and carried out the following process. 30 minutes at 45 ° C for reverse transcription, 5 minutes at 95 ° C for denaturation, 45 times for PCR (15 seconds at 94 ° C, 15 seconds at 55 ° C, 15 seconds at 72 ° C), last 5 minutes at 72 °C.
  • the reaction mixture was added to the simplified chamber formed on the slide surface, and PCR, heat denaturation, and hybridization were performed in the same manner as in Example 1.
  • the slides were washed as in Example 1 and fluorescence was measured by a laser scanner.
  • the first sample was subjected to reverse transcription and reverse transcription in a reaction mixture in which forward primers (B2-F, E1-F, C3-F, A2-F) and reverse primers (A2-R) were present in equal amounts (5 pmol).
  • forward primers B2-F, E1-F, C3-F, A2-F
  • reverse primers A2-R
  • PCR products were separated and purified to hybridize with B2-P capture probes fixed on glass slides in 3 ⁇ SSC solution for 1 hour at 50 ° C. (FIG. 4A).
  • a second sample was prepared by performing reverse transcription, symmetric PCR and hybridization on glass slides with capture probes fixed (FIG. 4B).
  • the third sample was subjected to reverse transcription and asymmetric PCR of extracted RNA in the presence of 5 pmol forward primers (B2-F, E1-F, C3-F, A2-F) and 50 pmol reverse privacy (A2-R).
  • PCR product was purified by separation and prepared by hybridization with capture probe B2-P fixed on a glass slide in 3X SSC solution at 55 ° C. for 1 hour (FIG. 4C).
  • the fourth sample was reacted on a glass slide to which capture probe B2-P was immobilized (buffer (50 mM Tris-HCl, pH 8.3), 50 mM KCl), 100 uM dNTPs, 2.5 mM MgCl 2 , 2U Taq DNA polymerase, and 40U reverse transcriptase) and 1 ⁇ g RNA were added and prepared by reverse transcription, asymmetric PCR and hybridization (FIG. 4D). Fluorescence was measured using a LAS4000 image analyzer. The results are shown in FIG.
  • Total RNA was extracted from K562 cell line (b3a2 positive) and HeLa cell line (b3a2 negative) cell lines to determine the detection limit of DNA microarrays using the integrated reverse transcription, asymmetric PCR and hybridization reaction. After quantifying the amount of b3a2 RNA of the K562 cell line and the ABL RNA of the HeLa cell line by real-time PCR, 0.1 to 1X10 6 copies of the b3a2 RNA in 1 ⁇ 10 6 copies of the ABL RNA were extracted at various concentrations. After mixing, integrated reverse transcription, asymmetric PCR, and hybridization reactions were performed.
  • the ratio of b3a2 / ABL RNA was detected up to 10 ⁇ 5 (b3a2 10 copies) for singleplex PCR, and up to about 10 ⁇ 4 (b3a2 200 copies) for multiplex PCR. .
  • K562 cells and HeLa cell line used as a control it was confirmed that it has b3a2 and normal ABL RNA as previously known. The results were confirmed to be identical to the type of chronic myeloid leukemia identified using conventional methods.
  • the present invention relates to a capture probe and primer set for chronic myeloid leukemia fusion genotyping typing and a method for detecting chronic myeloid leukemia fusion genotype type using the same, and because it integrates reverse transcription, asymmetric polymerase chain reaction, and hybridization, Compared to the leukemia fusion genotype type detection method, the sensitivity is significantly improved, the detection time is shortened, and the detection step is automated. In addition, there is an advantage that the specificity of the capture probe and primer is very high.
  • the capture probe and primer set for chronic myelogenous leukemia fusion genotype typing of the present invention can be used as a tool to detect chronic myeloid leukemia type early and more effectively to treat chronic myeloid leukemia and to determine its prognosis. have.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une sonde de capture pour le typage d'un génotype de fusion de leucémie myéloïde chronique, un jeu d'amorces et un procédé pour la détection d'un génotype de fusion de leucémie myéloïde chronique utilisant la sonde de capture et le jeu d'amorces. Plus particulièrement, la présente invention concerne une sonde de capture capable de détecter un type de protéine BCR-ABL modifiée en effectuant intégralement une réaction de transcription inverse, une réaction en chaîne par polymérase, une altération génétique et une hybridation à la surface d'un support solide. La présente invention concerne aussi un procédé de détection d'un type de protéine BCR-ABL modifiée, dans lequel une formation de complexe d'acides nucléiques ramifiés entre les ADN cibles amplifiés est favorisée, pour augmenter de cette façon de manière significative la sensibilité, la précision, etc. Un procédé pour la détection d'un génotype de fusion de leucémie myéloïde chronique selon la présente invention intègre une réaction de transcription inverse, une réaction asymétrique en chaîne par polymérase et une hybridation, et par conséquent le procédé de la présente invention peut améliorer de manière significative la sensibilité et raccourcir le temps pris pour la détection quand on compare avec des procédés classiques et peut permettre une automatisation des étapes de détection.
PCT/KR2013/000219 2012-01-12 2013-01-10 Sonde pour le typage du génotype de fusion de leucémie myéloïde chronique, amorce et leur procédé d'utilisation WO2013105801A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020120003808A KR101364761B1 (ko) 2012-01-12 2012-01-12 만성 골수성 백혈병 융합 유전자형 타이핑용 프로브, 프라이머 및 이의 이용방법
KR10-2012-0003808 2012-01-12

Publications (1)

Publication Number Publication Date
WO2013105801A1 true WO2013105801A1 (fr) 2013-07-18

Family

ID=48781691

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/000219 WO2013105801A1 (fr) 2012-01-12 2013-01-10 Sonde pour le typage du génotype de fusion de leucémie myéloïde chronique, amorce et leur procédé d'utilisation

Country Status (2)

Country Link
KR (1) KR101364761B1 (fr)
WO (1) WO2013105801A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662771A (zh) * 2020-12-30 2021-04-16 苏州大学附属第一医院 一种肿瘤融合基因的靶向捕获探针及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109033755A (zh) * 2018-07-27 2018-12-18 泰山医学院 基于大数据的融合基因数据检测方法、计算机程序、终端
CN109554474A (zh) * 2018-12-29 2019-04-02 中山大学达安基因股份有限公司 一种bcr-abl融合基因定量检测的方法及试剂盒
CN112410426B (zh) * 2020-11-17 2022-06-17 福州艾迪康医学检验所有限公司 用荧光pcr技术筛查和鉴定pax5重排相关融合基因的引物及探针、组合物和方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849400B1 (en) * 1997-07-23 2005-02-01 Gen-Probe Incorporated Methods for detecting and measuring spliced nucleic acids
KR20060000839A (ko) * 2004-06-29 2006-01-06 김동욱 Ｂｃｒ-ａｂｌ 정량키트
US7122313B2 (en) * 2001-08-17 2006-10-17 Trustees Of The University Of Pennsylvania Methods and kits for identifying and quantifying RNAs and DNAs associated with RNA and DNA binding proteins
KR100894511B1 (ko) * 2006-07-27 2009-04-24 가톨릭대학교 산학협력단 만성골수성백혈병 진단용 다중(ｍｕｌｔｉｐｌｅｘ)ＲＴ-ＰＣＲ용 프라이머, 이 프라이머를 포함하는 진단조성물 및 키트
US7700279B2 (en) * 1999-12-24 2010-04-20 Quest Diagnostics Investments Incorporated Assay for bcr/abl gene rearrangement
US20110072889A1 (en) * 2009-09-30 2011-03-31 Quest Diagnostics Investments Incorporated Bcr-abl truncation mutations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849400B1 (en) * 1997-07-23 2005-02-01 Gen-Probe Incorporated Methods for detecting and measuring spliced nucleic acids
US7700279B2 (en) * 1999-12-24 2010-04-20 Quest Diagnostics Investments Incorporated Assay for bcr/abl gene rearrangement
US7122313B2 (en) * 2001-08-17 2006-10-17 Trustees Of The University Of Pennsylvania Methods and kits for identifying and quantifying RNAs and DNAs associated with RNA and DNA binding proteins
KR20060000839A (ko) * 2004-06-29 2006-01-06 김동욱 Ｂｃｒ-ａｂｌ 정량키트
KR100894511B1 (ko) * 2006-07-27 2009-04-24 가톨릭대학교 산학협력단 만성골수성백혈병 진단용 다중(ｍｕｌｔｉｐｌｅｘ)ＲＴ-ＰＣＲ용 프라이머, 이 프라이머를 포함하는 진단조성물 및 키트
US20110072889A1 (en) * 2009-09-30 2011-03-31 Quest Diagnostics Investments Incorporated Bcr-abl truncation mutations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORTOLIN, SUSAN ET AL.: "Detection of BCR-ABL transcripts from the Philadelphia translocation by hybridization in microtiter wells and time-resolved immunofluorometry", CLINICAL CHEMISTRY, vol. 41, no. 5, May 1995 (1995-05-01), pages 693 - 699, XP002538359 *
MIKESKA, THOMAS ET AL.: "Validation of a primer optimisation matrix to improve the performance of reverse transcription quantitative real time PCR assays", BMC RESEARCH NOTES, vol. 2, 23 June 2009 (2009-06-23), pages 112, XP021060699 *
SANTINI, VALERIA ET AL.: "Detection of bacterial transcripts by RT-PCT and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogenic bone marrow transplantation", HAEMATOLOGIA, vol. 81, 1996, pages 201 - 207 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112662771A (zh) * 2020-12-30 2021-04-16 苏州大学附属第一医院 一种肿瘤融合基因的靶向捕获探针及其应用
CN112662771B (zh) * 2020-12-30 2024-04-02 苏州大学附属第一医院 一种肿瘤融合基因的靶向捕获探针及其应用

Also Published As

Publication number Publication date
KR20130083185A (ko) 2013-07-22
KR101364761B1 (ko) 2014-02-18

Similar Documents

Publication Publication Date Title
WO2011055916A2 (fr) Procédé de détection de la méthylation de gènes marqueurs de méthylation spécifiques du cancer du côlon pour le diagnostic du cancer du côlon
WO2013041031A1 (fr) Procédé de mesure d'une variation du nombre de copies d'un gène
WO2012070861A2 (fr) Biomarqueur de méthylation spécifique du cancer de l'estomac pour le diagnostic du cancer de l'estomac
WO2014073785A1 (fr) Procédé permettant de détecter les polypes gastriques et le cancer gastrique à l'aide d'un gène marqueur du polype gastrique et de la méthylation spécifique du cancer gastrique
WO2015183025A1 (fr) Procédé permettant la détection sensible d'adn cible à l'aide d'une nucléase spécifique de cible
WO2013105801A1 (fr) Sonde pour le typage du génotype de fusion de leucémie myéloïde chronique, amorce et leur procédé d'utilisation
WO2017122896A1 (fr) Marqueur génétique servant à distinguer et à détecter le virus responsable d'une maladie infectieuse touchant les poissons marins, et procédé de distinction et de détection du virus causal utilisant le marqueur
WO2019107893A2 (fr) Procédé d'amplification d'acide nucléique cible et composition associée
WO2012081928A2 (fr) Procédé pour la détection de la méthylation du gène gpm6a marqueur de méthylation spécifique au cancer des intestins en vue du diagnostic du cancer des intestins
WO2019013451A1 (fr) Adn polymérase présentant une spécificité de mutation génique accrue et composition tampon de pcr permettant d'accroître l'activité de ladite adn polymérase
WO2021075797A2 (fr) Composition pour le diagnostic de cancer du foie à l'aide de modifications de la méthylation de cpg dans des gènes spécifiques et son utilisation
WO2017082503A1 (fr) Sonde d'acide nucléique peptidique pour la détection multiplexée de mutations génétiques associées à un néoplasme myéloproliférateur bcr/abl négatif, composition pour la détection multiplexée de mutations génétiques la contenant, kit de détection multiplexée et procédé de détection multiplexée de mutations génétiques
WO2018080225A2 (fr) Marqueur de snp d'identification d'espèce de mouches nécrophages et son utilisation
WO2018139826A1 (fr) Procédé de prédiction de l'âge faisant appel à la méthylation de l'adn
WO2022075788A1 (fr) Composition pour diagnostiquer un cancer colorectal, un cancer rectal ou un adénome colorectal à l'aide d'un changement de méthylation cpg du gène linc01798, et son utilisation
WO2024043743A1 (fr) Composition pour l'amplification du gène flt3 et ses utilisations
WO2022097844A1 (fr) Procédé pour prédire le pronostic de survie de patients atteints de cancer pancréatique en utilisant les informations sur la variation du nombre de copies de gènes
WO2011132989A2 (fr) Marqueur de méthylation pour le diagnostic du cancer cervical
WO2019168261A1 (fr) Procédé d'analyse qualitative ou quantitative de génotype mutant et kit de pcr en temps réel pour la mise en œuvre de ce procédé
WO2021154009A1 (fr) Composition utilisant des changements de méthylation cpg dans des gènes spécifiques pour diagnostiquer le cancer de la vessie, et son utilisation
WO2017007241A1 (fr) Procédé pour déterminer la sensibilité à un inhibiteur simultané contre la parp et la tankyrase
WO2011139032A2 (fr) Composition d'amorces permettant d'amplifier une région génique présentant diverses modifications dans un gène cible
WO2014038890A1 (fr) Protéine de fusion comprenant axl et composition pour le traitement du cancer la comprenant
WO2022216066A1 (fr) Biomarqueur pour l'estimation du pronostic chez des patients atteints de cancer et son utilisation
WO2011136462A1 (fr) Procédé de détection de mutation génétique au moyen d'une amorce de blocage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13735698

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13735698

Country of ref document: EP

Kind code of ref document: A1